Tolerance to islet autoantigens in type 1 diabetes

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 131-161

  Bach, J F ^a   Chatenoud, L ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

CD3; GAD; Immunoregulation; Insulin; Th2

Indexed keywords

AUTOANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CELL ANTIGEN; CYTOKINE; GLUTAMATE DECARBOXYLASE; GLYCOPROTEIN GP 39; INSULIN; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY CD3; PADGEM PROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLONAL ANERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; ANTIGEN PRESENTATION; AUTOANTIGENS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLONAL ANERGY; CLONAL DELETION; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; ISLETS OF LANGERHANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; MUROMONAB-CD3; PREDIABETIC STATE; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 0035061536     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.131     Document Type: Review

References (155)

1. Insulin-dependent diabetes mellitus as an autoimmune disease
2. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD
3. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells
4. Glutamate decarboxylase and GABA in pancreatic islets: Lessons from knock-out mice
5. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes
6. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
7. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus
8. Peripheral-antigen-expressing cells in thymic medulla: Factors in self-tolerance and autoimmunity
9. Prevention of diabetes and insulitis by neonatal intrathymic islet administration in NOD mice
10. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice
11. Prevention of overt diabetes and insulitis by intrathymic injection of syngeneic islets in newborn nonobese diabetic (NOD) mice
12. Prevention of diabetes in BB/Wor rats by intrathymic islet injection
13. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth
14. + diabetogenic T-cells resulting in tolerance to autoimmune IDDM
15. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model
16. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
17. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity
18. + T cells
19. Escape from self-tolerance leads to neonatal insulin-dependent diabetes mellitus
20. +) T cell-mediated spontaneous diabetes in neonatal mice
21. Regulatory T cells in autoimmmunity
22. Regulatory T cells: Key controllers of immunologic self-tolerance
23. Control of immune pathology by regulatory T cells
24. Thymus and reproduction: Sex-linked dysgenesia of the gonad after neonatal thymectomy in mice
25. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation
26. The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients
27. - thymocytes that express L-selectin protect rats from diabetes upon adoptive transfer
28. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning
29. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice
30. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice
31. +) thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse
32. + immunoregulatory T cells that control autoimmune diabetes
33. +) T cells that prevent diabetes onset in nonobese diabetic mice
34. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
35. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse
36. Interleukin-13 prevents autoimmune diabetes in NOD mice
37. The significance of immune suppression in normal self tolerance
38. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity
39. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance
40. Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens
41. Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model
42. Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse
43. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice
44. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice
45. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma
46. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes
47. Interleukin-4 deficiency does not exacerbate disease in NOD mice
48. + T cells in the initiation of insulin-dependent diabetes mellitus
49. Are there unique autoantigens triggering autoimmune diseases?
50. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule
51. Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II
52. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: Analysis of a new "speed congenic" stock of NOD.Ig mu(null) mice
53. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice
54. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice
55. Molecular mimicry and autoimmunity
56. Cellular immunity to a determinant common to glutamate decarboxylase and Coxsackie virus in insulin-dependent diabetes
57. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry
58. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis
59. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma
60. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
61. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology
62. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes
63. Absence of B7-dependent responses in CD28-deficient mice
64. Beta cell apoptosis in T cell-mediated autoimmune diabetes
65. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice
66. Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes
67. High incidence of thyroiditis and antithyroid autoantibodies in NOD mice
68. Hemolytic anemia in non-obese diabetic mice
69. Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice
70. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes
71. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice
72. Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence
73. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice
74. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice
75. Effect of adjuvant therapy on development of diabetes in mouse and man
76. Protection from autoimmune diabetes by adjuvant therapy in the non-obese diabetic mouse: The role of interleukin-4 and interleukin-10
77. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease
78. An Abd transgene prevents diabetes in nonobese diabetic mice by inducing regulatory T cells
79. Failure of a protective major histocompatibility complex class II molecule to delete autoreactive T cells in autoimmune diabetes
80. Genetic control of diabetes progression
81. The NOD Idd9 genetic intervcal influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137
82. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes
83. Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/Ity/Bcg genes on chromosome 1
84. Neonatal induction of allogeneic tolerance prevents T cell-mediated autoimmunity in NOD mice
85. Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease
86. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice
87. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders
88. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein
89. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes
90. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice
91. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice
92. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals
93. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment
94. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy
95. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
96. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
97. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
98. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription
99. Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice
100. Gamma delta T cells as mediators of mucosal tolerance: The autoimmune diabetes model
101. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes
102. Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes
103. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein
104. Peptide therapy for diabetes in NOD mice
105. Secretory granule autoantigen in insulin-dependent diabetes mellitus is related to 62 kDa heat-shock protein (hsp60)
106. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
107. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
108. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277
109. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens
110. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens
111. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent
112. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E
113. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
114. Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides
115. GAD65 and insulin B chain peptide (9-23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat
116. Treatment with GAD65 or BSA does not protect against diabetes in BB rats
117. Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: A protocol effective in NOD mice may exacerbate disease in BB rats
118. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse
119. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice
120. Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice
121. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage
122. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody
123. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice
124. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
125. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes
126. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum
127. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody
128. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets
129. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: Transfer of protection by splenic T cells
130. Short-term administration of anti-L3T4 MoAb prevents diabetes in NOD mice
131. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes
132. The use of a non-depleting anti-CD4 monoclonal antibody to reestablish tolerance to beta cells in NOD mice
133. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice
134. Thymus-dependent monoclonal antibody-induced protection from transferred diabetes
135. Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice
136. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation
137. Mouse CD1-specific NK1 T cells: Development, specificity, and function
138. +)-like thymocytes in the NOD mouse
139. +T cells that promptly produce interleukin 4
140. Overexpression of natural killer T cells protects V alpha 14-J alpha 281 transgenic nonobese diabetic mice against diabetes
141. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
142. + T cells in a TH2 response and in immunoglobulin E production
143. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells
144. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells
145. Insulin prophylaxis in individuals at high risk of type I diabetes
146. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM
147. Intranasal insulin trial (INIT) in preclinical type 1 diabetes. 10th Int. Congress of Mucosal Immunol., Amsterdam, Netherlands, June, 27-July 1, 1999
148. Induction ofautoimmune diabetes by oral administration of autoantigen
149. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids
150. Characterization of immunodominant peptide determinants of IDDM-associated autoantigens in the NOD mouse
151. Characterization of novel T-cell epitopes on 65 kDa and 67 kDa glutamic acid decarboxylase relevant in autoimmune responses in NOD mice
152. Epitope dominance: Evidence for reciprocal determinant spreading to glutamic acid decarboxylase in non-obese diabetic mice
153. Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide
154. Peripheral T cell clones from NOD mice specific for GAD65 peptides: Lack of islet responsiveness or diabetogenicity
155. Antigen based therapies to prevent diabetes in NOD mice